Table 5.
Agreement in responsea and remissionb for patient-rated IDS-SR30 compared with patient-rated QIDS-SR16 at week 10 (acute-phase end point) and month 6 (continuation-phase end point); n (%) of patients.
| QIDS-SR16 |
||||||
|---|---|---|---|---|---|---|
| Week 10 |
Month 6 |
|||||
| Yes | No | κ | Yes | No | κ | |
| IDS-SR30 responder | 0.79* | 0.72* | ||||
| Yes | 487 (93) | 37 (7) | 328 (94) | 20 (6) | ||
| No | 36 (14) | 225 (86) | 19 (22) | 68 (78) | ||
| IDS-SR30 remitter | 0.71* | 0.69* | ||||
| Yes | 285 (74) | 100 (26) | 241 (82) | 52 (18) | ||
| No | 13 (3) | 387 (97) | 11 (8) | 131 (92) | ||
IDS-SR30, 30-item Inventory of Depressive Symptomatology—Self-Report; κ, kappa statistic; QIDS-SR16, 16-item Quick Inventory of Depressive Symptomatology—Self-Report.
a
Response: 50% reduction from baseline on IDS-SR30 and QIDS-SR16 total score.
b
Remission: IDS-SR30 total score≤13 and QIDS-SR16 total score≤5.
*
P<0.0001.